Kymera Therapeutics
KYMR
$120.23
-4.24%
Kymera Therapeutics is a clinical-stage biopharmaceutical company pioneering targeted protein degradation (TPD) therapies, leveraging its proprietary degrader platform to address diseases with known biology but previously undruggable targets, such as STAT6 and IRAK4. The company is a leader in the TPD space, differentiated by its ability to design small molecules that harness the ubiquitin-proteasome system to eliminate disease-causing proteins. Currently, the stock is in the spotlight due to a remarkable 181% surge over the past year, driven by promising clinical data and strategic partnerships, while investors debate the sustainability of this momentum given the company's pre-revenue stage and heavy R&D spending.…
KYMR
Kymera Therapeutics
$120.23
Investment Opinion: Should I buy KYMR Today?
Rating: Buy. Kymera is a high-risk, high-reward investment with a Strong Buy consensus from 22 analysts and an average target price of $130.91, implying 9.3% upside. The thesis is that its TPD platform has the potential to address multiple undruggable targets, and recent clinical progress justifies the premium valuation. The company's strong balance sheet (current ratio 10.47, D/E 0.05) provides a runway to advance its pipeline without immediate financing pressure.
Sign up to view all
KYMR 12-Month Price Forecast
The AI assessment leans bullish, driven by the strong analyst support, robust balance sheet, and the potential of the TPD platform. However, confidence is medium due to the extreme valuation and the binary nature of clinical trials. The stock's momentum and recent data readouts suggest upside, but any negative news could trigger a sharp correction. Key factors to watch are the upcoming STAT6 data and any partnership announcements. If the stock breaks above $130 on strong data, the stance would be upgraded to high confidence; if it falls below $100, the stance would be downgraded to neutral.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Kymera Therapeutics's 12-month outlook, with a consensus price target around $130.91 and implied upside of +8.9% versus the current price.
Average Target
$130.91
0 analysts
Implied Upside
+8.9%
vs. current price
Analyst Count
—
covering this stock
Price Range
$111 - $155
Analyst target range
Kymera is covered by 22 analysts, with a consensus recommendation of 'Strong Buy' (mean score of 1.42 on a 1-5 scale, where 1 is Strong Buy). The average target price is $130.91, implying an upside of 9.3% from the current price of $119.80. The distribution is heavily bullish, with no sell ratings and only a few holds, reflecting strong confidence in the company's pipeline and technology. The target range spans from $111.00 (low) to $155.00 (high), indicating a moderate spread of about 40% between the most bearish and bullish targets. The high target of $155 suggests potential for further upside if clinical data continues to impress, while the low target of $111 implies a modest downside if setbacks occur. Recent ratings actions have been predominantly positive, with firms like UBS, Citigroup, and BTIG reiterating Buy ratings, though Wolfe Research downgraded from Outperform to Peer Perform in January 2026, signaling some caution. Overall, the analyst community is highly optimistic, but the wide range highlights the inherent uncertainty in clinical-stage biotech investing.
Bulls vs Bears: KYMR Investment Factors
Kymera presents a classic high-risk, high-reward biotech investment. The bull case is anchored by a differentiated TPD platform, strong analyst support, and a solid balance sheet, while the bear case centers on an extreme valuation (167.5x PS), pre-revenue status, and widening losses. Currently, the bull evidence is stronger given the recent clinical momentum and consensus Strong Buy rating, but the sustainability of the 181% rally is questionable. The key tension is whether the market's lofty expectations for the platform's commercial potential will be validated by upcoming clinical data, particularly for STAT6 and IRAK4 programs. If trials succeed, the stock could re-rate higher; if they fail, the downside is severe given the valuation.
Bullish
- 181% 1-Year Price Surge: KYMR has delivered a remarkable 181.3% return over the past year, far outpacing the S&P 500's 20.5% gain. This momentum reflects strong investor confidence in its targeted protein degradation platform and recent clinical progress.
- Strong Buy Analyst Consensus: With 22 analysts covering the stock, the consensus is a Strong Buy (mean score 1.42 on a 1-5 scale), and the average price target of $130.91 implies 9.3% upside from the current $119.80. No sell ratings exist, indicating broad institutional optimism.
- Robust Balance Sheet: The company has a current ratio of 10.47 and a debt-to-equity ratio of just 0.05, indicating ample liquidity and minimal leverage. This financial stability supports continued R&D investment without immediate dilution risk.
- Platform Potential in TPD: Kymera's proprietary degrader platform targets previously undruggable proteins like STAT6 and IRAK4, addressing high unmet medical needs. This differentiation could lead to significant value creation if clinical trials succeed.
Bearish
- Extreme Valuation Premium: KYMR trades at a PS ratio of 167.5x trailing, over 15x the biotech industry average of ~10x. This implies the market is pricing in massive future revenue that may never materialize if trials fail.
- Pre-Revenue with Widening Losses: Q4 2025 revenue was just $2.86M, down 61.3% YoY, while net losses widened to $87.03M from $65.58M in Q1 2025. The company is burning cash at an accelerating rate, with negative free cash flow of -$234M TTM.
- High Beta and Volatility: With a beta of 1.95, KYMR is highly sensitive to market swings. The stock's max drawdown of -27.7% over the past year highlights the risk of sharp corrections, especially in a risk-off environment.
- Analyst Target Range Signals Uncertainty: The analyst target range spans from $111 (low) to $155 (high), a 40% spread. This wide dispersion reflects the inherent uncertainty in clinical-stage biotech, where binary outcomes can dramatically alter valuations.
KYMR Technical Analysis
Kymera's stock is in a powerful uptrend, with a 1-year price change of +181.3%, and the current price of $119.80 sits near the upper end of its 52-week range, at approximately 92% of the range (from $39.84 low to $130.05 high). This positioning near the highs reflects strong bullish momentum and investor confidence, though it also raises concerns about potential overextension. The stock has outperformed the S&P 500 dramatically, with relative strength of 160.8% over the past year, indicating a high-beta, high-momentum profile.
Beta
1.95
1.95x market volatility
Max Drawdown
-27.7%
Largest decline past year
52-Week Range
$40-$130
Price range past year
Annual Return
+184.5%
Cumulative gain past year
| Period | KYMR Return | S&P 500 |
|---|---|---|
| 1m | +13.3% | +4.1% |
| 3m | +47.7% | +1.9% |
| 6m | +31.6% | +12.4% |
| 1y | +184.5% | +19.3% |
| ytd | +65.2% | +13.1% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
KYMR Fundamental Analysis
Kymera is a clinical-stage biotech with minimal revenue; the most recent quarter (Q4 2025) reported revenue of $2.86 million, down 61.3% year-over-year, reflecting the lumpy nature of collaboration revenue. The company is deeply unprofitable, with a net loss of $87.03 million in Q4 2025, and an EPS of -$0.98. Gross margin was 27.6% in Q4, but this is not indicative of core operations as it includes collaboration revenue; the company's operating margin was -34.2%, and R&D expenses were $83.86 million, highlighting the heavy investment in its pipeline. The trajectory shows widening losses from $65.58 million in Q1 2025 to $87.03 million in Q4, indicating accelerating spending as clinical programs advance.
Quarterly Revenue
$2860000.0B
2025-12
Revenue YoY Growth
-61.3%
YoY Comparison
Gross Margin
N/A
Latest Quarter
Free Cash Flow
$-234340000.0B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Open an Account, get $2 TSLA now!
Valuation Analysis: Is KYMR Overvalued?
Given that Kymera has negative net income and EBITDA, the most appropriate valuation metric is the price-to-sales (PS) ratio, which stands at 167.5x trailing, while the EV/Sales is 90.4x. These astronomical multiples reflect the market's expectation of massive future revenue growth from its TPD platform, but they also imply extreme risk if clinical trials fail. Compared to the biotech industry average PS ratio of around 10x (based on typical sector data), Kymera trades at a premium of over 1,500%, which is unjustified by current fundamentals but may be rationalized by the potential of its platform. Historically, Kymera's PS ratio has ranged from 31x to 2,296x over the past few years, and the current 167.5x is in the mid-range, suggesting the market is pricing in significant but not unprecedented optimism.
PE
-21.1x
Latest Quarter
vs. Historical
N/A
5-Year PE Range 17x~59x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
-20.8x
Enterprise Value Multiple
Investment Risk Disclosure
Financial and operational risks are substantial. Kymera is pre-revenue with minimal collaboration revenue ($2.86M in Q4 2025, down 61% YoY), and net losses are widening, from $65.58M in Q1 2025 to $87.03M in Q4 2025. The company's negative free cash flow of -$234M TTM indicates heavy cash burn, though the current ratio of 10.47 and low debt-to-equity of 0.05 provide a cushion. However, if clinical trials stall, the company may need to raise capital through dilutive offerings, pressuring the stock. R&D expenses of $83.86M in Q4 alone highlight the cost of advancing the pipeline, and the operating margin of -34.2% underscores the lack of profitability.
FAQ
The key risks of holding KYMR are: (1) Clinical trial failure, which is the most severe risk, as a single failed trial could wipe out most of the stock's value; (2) Valuation compression, given the extreme PS ratio of 167.5x, which could contract sharply if sentiment turns negative; (3) Dilution risk, as the company may need to raise capital to fund operations, given its negative free cash flow of -$234M TTM; and (4) Market risk, as the stock's beta of 1.95 makes it highly sensitive to market downturns. The short ratio of 15.62 also indicates potential for volatility.
The 12-month forecast for KYMR is bullish, with a base case target of $130.91 (analyst average), implying 9.3% upside. The bull case target is $155 (analyst high), a 29.4% gain, with a 30% probability, driven by positive clinical data and partnerships. The bear case target is $111 (analyst low), a 7.3% decline, with a 20% probability, if trials disappoint. The base case, with a 50% probability, assumes steady progress without major setbacks. Overall, the most likely scenario is modest upside, but the wide range reflects the high uncertainty in clinical-stage biotech.
KYMR is significantly overvalued based on traditional metrics. The PS ratio of 167.5x is over 15x the biotech industry average of ~10x, implying the market expects massive future revenue growth. The EV/Sales ratio of 90.4x is also extremely high. However, the stock's valuation is in the mid-range of its historical PS range of 31x to 2,296x, suggesting the market is pricing in substantial but not unprecedented optimism. The valuation implies the market expects the company to successfully commercialize its TPD platform and generate billions in revenue. If clinical trials succeed, the stock could be undervalued; if they fail, it is grossly overvalued.
KYMR is a high-risk, high-reward stock that could be a good buy for investors with a high risk tolerance and a long-term horizon. The analyst consensus is Strong Buy, with an average target price of $130.91, implying 9.3% upside from the current price of $119.80. However, the stock trades at a PS ratio of 167.5x, which is extremely expensive and leaves little room for error. The biggest downside risk is a clinical trial failure, which could send the stock to its 52-week low of $39.84, a 66.7% decline. Therefore, it is a good buy only if you believe in the TPD platform's potential and can withstand significant volatility.
KYMR is more suitable for long-term investment, given its clinical-stage nature and the multi-year timeline to potential commercialization. The stock's high beta of 1.95 and max drawdown of -27.7% make it unsuitable for short-term trading unless you have a high risk tolerance and can time market swings. The company has no dividend and is pre-revenue, so returns depend entirely on capital appreciation. A minimum holding period of 3-5 years is recommended to allow clinical trials to mature and the platform to generate value. Short-term traders may find opportunities in the volatility, but the risk is substantial.